ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (338 K)

Article Toolbox
 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.bbamcr.2005.03.010    
How to Cite or Link Using DOI (Opens New Window)

Copyright © 2005 Elsevier B.V. All rights reserved.

Review

Bridging advanced glycation end product, receptor for advanced glycation end product and nitric oxide with hormonal replacement/estrogen therapy in healthy versus diabetic postmenopausal women: A perspective

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Srirupa Mukhopadhyay and Tapan K. MukherjeeCorresponding Author Contact Information, E-mail The Corresponding Author

Pulmonary Division, Department of Internal Medicine, University of Utah Health Science Center, Rm 725 Wintrobe Building, 26 North 1900 East, Salt Lake City, UT: 84132-4701, USA


Received 8 February 2005; 
revised 20 March 2005; 
accepted 22 March 2005. 
Available online 8 April 2005.

Abstract

Cardiovascular diseases (CVD) are the most significant cause of death in postmenopausal women. The loss of estrogen biosynthesis with advanced age is suggested as one of the major causes of higher CVD in postmenopausal women. While some studies show beneficial effects of estrogen therapy (ET)/hormonal replacement therapy (HRT) in the cardiovascular system of healthy postmenopausal women, similar studies in diabetic counterparts contradict these findings. In particular, ET/HRT in diabetic postmenopausal women results in a seemingly detrimental effect on the cardiovascular system. In this review, the comparative role of estrogens is discussed in the context of CVD in both healthy and diabetic postmenopausal women in regard to the synthesis or expression of proinflammatory molecules like advanced glycation end products (AGEs), receptor for advanced glycation end products (RAGEs), inducible nitric oxide synthases (iNOS) and the anti-inflammatory endothelial nitric oxide synthases (eNOS). The interaction of AGE–RAGE signaling with molecular nitric oxide (NO) may determine the level of reactive oxygen species (ROS) and influence the overall redox status of the vascular microenvironment that may further determine the ultimate outcome of the effects of estrogens on the CVD in healthy versus diabetic women.

Keywords: AGE; RAGE; Estrogen; HRT; ET; Diabetes; NO; ROS; Postmenopausal women

Article Outline

1. Background
2. Role of estrogen in the context of cardiovascular disorders in healthy premenopausal and postmenopausal women
3. Estrogen and cardiovascular disorders in premenopausal diabetic women
4. Paradox of the effect of HRT on the cardiovascular disorders in postmenopausal diabetic women: clinical studies
5. Paradox of the recent in vitro experimental results on estrogen and cardiovascular disorders
6. Functional abnormalities of vascular system in diabetes and its relationship with estrogen
7. Advanced glycation end products (AGEs) as a vascular proinflammatory molecule
8. Receptor-independent actions of advanced glycation end products (AGEs) in vascular dysfunction
9. Receptor-dependent action of advanced glycation end products (AGEs) in vascular dysfunction
10. AGE–RAGE interaction causes subcellular signaling leading to the generation of ROS and vascular dysfunction
11. Effect of estrogen as an inducer of AGE–RAGE signaling
12. Possible role of estrogen in RAGE signaling in homeostasis versus pathophysiological conditions
13. Bridging of NO and ROS as effector molecules with AGE–RAGE signaling in diabetes
14. Effects of estrogen on nitric oxide signaling in healthy versus diabetic subjects
15. The influence of overall oxidative stress on the vascular system of diabetic subjects
16. Role of estrogen in controlling the overall oxidative stress of diabetic vasculature
17. Conclusion
Acknowledgements
References





Corresponding Author Contact InformationCorresponding author. Tel.: +1 801 581 7806; fax: +1 801 585 3355.

 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.